Cargando…
Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
BACKGROUND: Pediatric patients with advanced chronic kidney disease (CKD) are often prescribed oral phosphate binders (PBs) for the management of hyperphosphatemia. However, available PBs have limitations, including unfavorable tolerability and safety. METHODS: This phase 3, multicenter, randomized,...
Autores principales: | Greenbaum, Larry A., Jeck, Nikola, Klaus, Günter, Fila, Marc, Stoica, Cristina, Fathallah-Shaykh, Sahar, Paredes, Ana, Wickman, Larysa, Nelson, Raoul, Swinford, Rita D., Abitbol, Carolyn Larkins, Balgradean, Mihaela, Jankauskiene, Augustina, Perrin, Amandine, Enoiu, Milica, Ahn, Sun-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009783/ https://www.ncbi.nlm.nih.gov/pubmed/33106892 http://dx.doi.org/10.1007/s00467-020-04805-y |
Ejemplares similares
-
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric
Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014) -
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017) -
Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017) -
Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018) -
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)